Gene Expression Atlas home | about the project | faq | feedback | blog | das | api | help
RBL2
REST API REST API
Homo sapiens
RBL2 is differentially expressed in 315 experiments: 128 organism parts: prostate, cerebellum, ... (126 more);, 213 disease states: normal, control, ... (211 more);, 107 cell types 383 cell lines 41 compound treatments and 87 other conditions.
Synonyms p130, Rb2
Orthologs Rbl2 (Mus musculus)   ENSGALG00000003663 (Gallus gallus)   Rbl2 (Rattus norvegicus)   RBL2 (Danio rerio)   LOC425111 (Gallus gallus)   ENSCING00000004590 (Ciona intestinalis)   A5D7M0_BOVIN (Bos taurus)   Rbf (Drosophila melanogaster)   Rbf2 (Drosophila melanogaster)   rbl2 (Xenopus laevis)   RBL2 (Canis familiaris)   (Compare orthologs)
Gene Ontology Term DNA binding, protein binding, regulation of transcription, DNA-dependent, cytoplasm, regulation of cell cycle, nucleus, transcription factor complex, chromatin modification, chromatin, nucleolus, regulation of lipid kinase activity
InterPro Term Cyclin-like, RB_A, RB_B, DUF3452_retinoblatoma-assoc
UniProt Accession Q08999, F5H837, E9PG04, B7Z913
Search EB-eye ENSG00000103479
Show more properties
Experimental Factors
Organism part

studied in E-GEOD-803, E-GEOD-6573, E-GEOD-1577, E-GEOD-7540, E-GEOD-3526, ... (27 experiments)

3
1
Number of published studies where the gene is over/under expressed compared to the gene's overall mean expression level in the study.

anatomogram

Cell line

studied in E-GEOD-17482, E-GEOD-5258, E-MEXP-1006, E-GEOD-19639, E-GEOD-18005, ... (35 experiments)

Factor Value U/D Experiments
MDA-MB-231
3
E-TABM-420, E-MTAB-62, E-GEOD-5823
CCRFCEM
2
E-MTAB-37, E-GEOD-24147
DU145
2
E-GEOD-17482, E-GEOD-20089
LNCaP
2
E-GEOD-14990, E-GEOD-14464
MCF-7
2
E-GEOD-19639, E-GEOD-20081
MDA468
2
E-MTAB-62, E-MEXP-440
377 more value(s).


Cell type

studied in E-GEOD-21668, E-GEOD-20677, E-GEOD-2822, E-GEOD-21909, E-GEOD-21750, ... (52 experiments)

Factor Value U/D Experiments
CD8+ T cell
3
E-AFMX-5, E-TABM-145, E-GEOD-6740
CD56+ NK cells
2
E-AFMX-5, E-TABM-145
monocyte
2
E-GEOD-11755, E-MEXP-2019
CXCR4 positive
1
E-GEOD-15893
partially reprogrammed human induced pluripotent stem cell
1
E-GEOD-18265
CD34+
1
E-AFMX-5
101 more value(s).


Disease state

studied in E-GEOD-3307, E-GEOD-15960, E-GEOD-2466, E-MEXP-1121, E-GEOD-1577, ... (62 experiments)

Factor Value U/D Experiments
control
1
4
E-GEOD-21912, E-GEOD-8121, E-GEOD-16363, E-GEOD-3185, E-GEOD-20602 ... (5 experiments)
lung adenocarcinoma
1
3
E-MTAB-37, E-MTAB-62, E-GEOD-2514, E-MEXP-231
synovial sarcoma
2
E-GEOD-6481, E-MTAB-37
glioblastoma
2
E-MTAB-62, E-GEOD-4412
retinoblastoma
2
E-MTAB-37, E-GEOD-96
uterine fibroid
2
E-MTAB-62, E-GEOD-7307
207 more value(s).


Compound treatment

studied in E-GEOD-5258, E-GEOD-3720, E-GEOD-5824, E-TABM-868, E-MEXP-1958, ... (28 experiments)

Factor Value U/D Experiments
none
4
7
E-GEOD-20719, E-GEOD-5824, E-MEXP-1601, E-GEOD-412, E-TABM-868, ... (11 experiments)
dimethyl sulfoxide
2
E-GEOD-6932, E-GEOD-5824
lipopolysaccharide
1
2
E-GEOD-3720, E-TABM-868, E-MEXP-1958
5-aza-2'-deoxycytidine + trichostatin A
1
E-MEXP-1269
NaOH
1
E-MEXP-2590
TNF
1
E-GEOD-15205
35 more value(s).


Agent

studied in E-GEOD-19519

Factor Value U/D Experiments
DMSO
1
1
E-GEOD-19519
thapsigargin
1
1
E-GEOD-19519
tunicamycin
1
E-GEOD-19519


Biosource provider
studied in E-MTAB-37

BioSourceProvider
studied in E-GEOD-19519, E-GEOD-19480

Blood/non-blood meta-groups
studied in E-MTAB-62

Bmngrd
studied in E-GEOD-20194, E-GEOD-16716

Cancer site
studied in E-GEOD-4271

cd1a
studied in E-GEOD-22601

cd3
studied in E-GEOD-22601

cd34
studied in E-GEOD-22601

cd4
studied in E-GEOD-22601

cd8
studied in E-GEOD-22601

Cell treatment
studied in E-MEXP-1192

Classifier
studied in E-GEOD-3493

Clinical history
studied in E-GEOD-22097, E-GEOD-19420, E-TABM-234, E-GEOD-19743, E-GEOD-7967, ... (11 experiments)

Clinical info
studied in E-GEOD-19743, E-MTAB-37, E-GEOD-6710, E-GEOD-19348, E-MEXP-1251, ... (8 experiments)

Clinical treatment
studied in E-GEOD-1743, E-GEOD-2171, E-GEOD-6532, E-GEOD-21610

coriell cell line repository identifier
studied in E-GEOD-19519

development stage
studied in E-GEOD-22601

Developmental stage
studied in E-GEOD-19743, E-GEOD-1614, E-GEOD-20033, E-MEXP-2359, E-GEOD-3891, ... (6 experiments)

dfs time (months)
studied in E-GEOD-21653

Disease staging
studied in E-GEOD-89, E-GEOD-19743, E-GEOD-3325, E-TABM-147, E-GEOD-21138, ... (7 experiments)

double amplification
studied in E-GEOD-22601

Environmental stress
studied in E-GEOD-1518, E-GEOD-3720, E-GEOD-4086

Epiregulin elisa conc ng ml
studied in E-GEOD-5851

Estrogen receptor status
studied in E-GEOD-6532, E-GEOD-20194, E-GEOD-16716

Ethnic group
studied in E-GEOD-20194, E-GEOD-16716

Ethnicity
studied in E-GEOD-21589, E-GEOD-16363

family id
studied in E-GEOD-19519

Genetic modification
studied in E-GEOD-8023, E-MEXP-1482, E-GEOD-7578, E-GEOD-20847, E-MTAB-108, ... (8 experiments)

Genotype
studied in E-GEOD-17476, E-GEOD-2466, E-GEOD-22593, E-GEOD-18005, E-TABM-868, ... (14 experiments)

369 groups
studied in E-MTAB-62

4 groups from blood to incompletely diff
studied in E-MTAB-62

96 groups
studied in E-MTAB-62

Growth condition
studied in E-MEXP-1220, E-GEOD-5681, E-GEOD-7011, E-MEXP-2657, E-TABM-127, ... (11 experiments)

Her2 fish
studied in E-GEOD-20194, E-GEOD-16716

Her2 ihc
studied in E-GEOD-20194, E-GEOD-16716

Histology
studied in E-TABM-234, E-GEOD-21653, E-TABM-276, E-GEOD-2748

Individual
studied in E-TABM-325, E-MTAB-197, E-GEOD-2466, E-MEXP-2069, E-GEOD-1926, ... (37 experiments)

Infection
studied in E-MEXP-1274, E-GEOD-2405, E-GEOD-12108, E-GEOD-9723, E-GEOD-980, ... (6 experiments)

Injury
studied in E-GEOD-19743

Irradiate
studied in E-GEOD-1977

Karyotype
studied in E-GEOD-7214

Labeling
studied in E-LGCL-5

Light
studied in E-GEOD-1725

Material type
studied in E-MEXP-455, E-GEOD-9171

Media
studied in E-MEXP-765

15 meta groups
studied in E-MTAB-62

4 meta groups
studied in E-MTAB-62

6 meta groups
studied in E-MTAB-62

Metastasis
studied in E-GEOD-18105

Molecular subtype
studied in E-GEOD-21653

Nbefore
studied in E-GEOD-20194, E-GEOD-16716

organ
studied in E-GEOD-24283

Organism
studied in E-GEOD-7540, E-GEOD-1801, E-GEOD-426, E-TABM-84

Organism status
studied in E-GEOD-19188

P53 ihc
studied in E-GEOD-21653

Performer
studied in E-GEOD-2004

Phase
studied in E-GEOD-4888

Phenotype
studied in E-GEOD-22309, E-GEOD-21750, E-GEOD-1657, E-GEOD-1460, E-MEXP-1403 ... (5 experiments)

Population
studied in E-MTAB-197, E-GEOD-4922, E-GEOD-4342

Progesterone receptor status
studied in E-GEOD-6532

Progression free survival of days
studied in E-GEOD-5851

Protocol type
studied in E-GEOD-22097, E-GEOD-3254, E-GEOD-19246

pt
studied in E-GEOD-21653

Replicate
studied in E-GEOD-10797, E-GEOD-18791

Rna integrity
studied in E-TABM-325

RNAi
studied in E-GEOD-12438, E-GEOD-1676, E-MEXP-101, E-GEOD-3697, E-MEXP-1857, ... (6 experiments)

Sample preparation
studied in E-GEOD-16728, E-GEOD-12710

sampleID
studied in E-GEOD-24283

Sampling time point
studied in E-GEOD-19743, E-GEOD-17400, E-GEOD-18995

Sex
studied in E-GEOD-19069, E-GEOD-2466, E-GEOD-7307

Sirna
studied in E-GEOD-21575

Stimulation
studied in E-GEOD-20114, E-GEOD-11886, E-GEOD-11428

stimulus
studied in E-GEOD-22103

Strain or line
studied in E-MEXP-1996

Subtype
studied in E-GEOD-24283

Survival time
studied in E-GEOD-3494, E-GEOD-19188

Tbefore
studied in E-GEOD-20194, E-GEOD-16716

Test result
studied in E-TABM-276, E-GEOD-2748

Transfection
studied in E-GEOD-14680

Treatment
studied in E-GEOD-22369, E-GEOD-22368, E-GEOD-16837, E-MEXP-973, E-GEOD-21909, ... (7 experiments)

Treatment code
studied in E-GEOD-20194, E-GEOD-16716

Treatments comments
studied in E-GEOD-20194, E-GEOD-16716

Treatments comments 99 146
studied in E-GEOD-20194, E-GEOD-16716

Tumor grading
studied in E-GEOD-4290, E-TABM-147

Tumor size
studied in E-GEOD-6532

Vehicle
studied in E-GEOD-5258

Processing time: 0.459 secs.
 
Gene Expression Atlas 2.0.11.1- 12/23/11 3:09:34 PM